INDP (Indaptus Therapeutics) Volatility: 105.65% (As of Jun. 25, 2026)


INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $3.55
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Volatility?

Indaptus Therapeutics INDP -5.46% 26 Volatility is 105.65% as of Jun. 25, 2026. GuruFocus rates INDP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-25), Indaptus Therapeutics's Volatility is 105.65%.

Indaptus Therapeutics  (NAS:INDP) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Indaptus Therapeutics Volatility Related Terms

INDP vs KPTI, NBP, IMUX: Volatility Comparison

For the Biotechnology subindustry, Indaptus Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Volatility falls into.


INDP
26GF Score
Indaptus Therapeutics Inc INDP
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics  (NAS:INDP) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 105.65% mean?
Indaptus Therapeutics (INDP) has a Volatility of 105.65% as of Jun. 25, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Indaptus Therapeutics and its competitors.
Is Indaptus Therapeutics' Volatility too high?
Indaptus Therapeutics' current Volatility is 105.65%. Overall, Indaptus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Indaptus Therapeutics' Volatility compare to KPTI and NBP?
Indaptus Therapeutics' Volatility of 105.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Indaptus Therapeutics and its competitors. Indaptus Therapeutics's current Volatility is 105.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indaptus Therapeutics stock overvalued right now?
Indaptus Therapeutics (INDP) has a current Volatility of 105.65%. The current Volatility is 105.65%. Indaptus Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Indaptus Therapeutics (INDP), the current Volatility is 105.65% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price